

XXI LIPID MEETING LEIPZIG

Leipzig, Germany | December 12–14, 2019



FINAL PROGRAM



UNIVERSITÄT
LEIPZIG

Medizinische Fakultät





About Sysmex

Lighting the way
with diagnostics



We at Sysmex have been delivering products and services in the field of healthcare testing to our customers at medical institutes on over 190 countries and regions worldwide. We now accept the challenge to open a new future in healthcare by testing limits and reshaping the world of diagnostics. The field of healthcare is in for great

changes, as testing and diagnostics provide ever more reliable guidelines. Progress in testing and diagnostics for genes, cells, and proteins is making it possible to better understand an individual's physical status and find the best possible treatment available for each patient.

www.sysmex.de

CONTENT

Welcome	5
Organizer	6
General Information	7
Program Overview	9
Lectures Friday	10
Lectures Saturday	12
Exhibition	13
Sponsors	14

Program
ONLINE



Poster
ONLINE



FLY TO MOUSE TO HUMAN

Metabolic and Behavioral Measurement Systems



Sable metabolic and behavioral measurement systems are designed by scientists, for scientists. You'll get the highest resolution and most accurate results, setting the quality standard that no other analyzers can match. And we provide world-class support in experimental design, system configuration, setup, training and ongoing support. Contact us for more information.



Visit us on LinkedIn



+49 30 5304 1002 sales@sablesys.com sablesys.com

WELCOME

The XXI Lipid Meeting Leipzig will be held at Leipziger Foren December 12-14, 2019.

Since its foundation more than twenty years ago, this meeting in the heart of Germany has developed into an established forum for scientific discussion and interdisciplinary collaboration in all relevant areas of lipid metabolism and diseases caused by metabolic disorders.

The international XXI Lipid Meeting Leipzig 2019 will give a high level update on genetic studies of lipid metabolism and lipid related diseases, recent developments in hematopoiesis research and atherosclerosis, new insights in brain lipid metabolism, metabolic syndrome and fatty liver disease, precise medicine in diagnostics, prevention and novel treatment strategies of lipid disorders.

The Lipid Meeting is open to all physicians, scientists and students interested in the fascinating field lipid function in medicine and physiology. It brings together an international group of participants from all career levels and from various scientific and medical disciplines to present cutting-edge research in a collegial atmosphere.

We hope to offer you an interesting and scientifically exciting meeting and look forward to welcoming you to Leipzig.

Prof. Dr. Joachim Thiery Prof. Dr. Uta Ceglarek PD Dr. Thorsten Kaiser
Institute of Laboratory Medicine, Clinical Chemistry and Molecular Diagnostics

ORGANIZER

SCIENTIFIC COMMITTEE

Prof. Dr. Joachim Thiery

Prof. Dr. Uta Ceglarek

PD Dr. Thorsten Kaiser

Universitätsklinikum Leipzig AöR

Institute of Laboratory Medicine,

Clinical Chemistry and Molecular Diagnostics

Paul-List-Straße 13–15

D-04103 Leipzig

Phone: +49 341-97 22-200

Fax: +49 341 97 22-209

E-Mail: Katja.Seidel@medizin.uni-leipzig.de

Homepage: www.lipidmeeting.de

CONFERENCE OFFICE

event lab. GmbH

Richard-Lehmann-Str. 12

D-04275 Leipzig

Phone: +49 341 308884-79

Fax: +49 341 308884-51

E-Mail: lipidmeeting@eventlab.org

Homepage: www.eventlab.org

SUPPORTED BY



Deutsche Forschungsgemeinschaft (DFG)



Deutsche Gesellschaft für Klinische Chemie und Laboratoriumsmedizin e.V.

(DGKL)

GENERAL INFORMATION

CONFERENCE VENUE

The conference takes place at Leipziger Foren. During the breaks, the industrial exhibition can be visited in the foyer of this location. The poster exhibition is located in room 2 + 3.

CONFERENCE DATES

Exhibition hours | Opening hours registration desk
Friday, December 13, 2019 08:00 am – 06:00 pm
Saturday, December 14, 2019 08:00 am – 03:00 pm

TECHNICAL FACILITIES | SPEAKER PREVIEW

Facilities will be available to present PowerPoint presentations. The files (USB flash drive) should be handed over to the technical support in the lecture hall no later than 30 minutes before the session starts.

POSTER EXHIBITION

The posters shall be mounted on Friday, December 13, 2019 until 12:00 pm. They should be removed on Saturday, December 14, 2019 until 02:00 pm at the latest. Material to fix the posters is available at the registration desk.

EDUCATION POINTS

The Medical Association of Saxony certified the meeting with 8 Points on Friday, December 13 and with 5 Points on December 14, 2019.

Wi-Fi

Free Wi-Fi is available in all rooms during the meeting.

Name: Michaelis-Konferenzetage Password: mg7cm8kc9

PUBLIC TRANSPORT

The venue can easily be reached by public transport.

Tram stop: Goerdelerstrasse, city center

SOCIAL PROGRAM

Opening Ceremony will take place at Salles de Pologne
Hainstraße 16–18, 04109 Leipzig
December 12, 2019 at 6:00 pm

Hand aufs Herz - Vorsorge rettet Leben

Alkoholismus

Adipositas

Rauchen

Diabetes

Infektionen

Ungesunde Ernährung



Triglyceride

hsCRP

HDL

LDL

Lp(a)

Cholesterin

Die Untersuchung der genannten Blutfette entdeckt nur etwa die Hälfte aller Herzinfarkt-gefährdeten Personen. Deshalb ist die frühzeitige Bestimmung weiterer Risikofaktoren wichtig.

Ihr starker Partner in der klinischen Chemie

Reagenzien, Kalibratoren und Kontrollen für Ihr Labor

CE-Kennzeichnung nach IVDR (EU) 2017/746

RiliBÄK-konforme Kontrollen

Bis zu drei Messbereiche

Präzise und zuverlässig

Universell einsetzbar

Gebrauchsfertig



PROGRAM OVERVIEW

THURSDAY, DECEMBER 12, 2019

06:00	Opening Ceremony and dinner at Salles de Pologne
11:00 pm	



FRIDAY, DECEMBER 13, 2019

08:30	Plenary Session 1
10:00 am	

10:00	Coffee Break
10:30 am	

10:30 am	WS 1: Lipids, fatty liver and obesity	WS 2: Risk factors and preventive strategies in cardiometabolic and brain diseases
12:30 pm		

12:30	Lunch Break
01:15 pm	

01:15	Symposium — Daiichi Sankyo Deutschland GmbH
02:15 pm	“Beyond statins: upcoming options in cholesterol therapy”

02:30	Plenary Session 2
04:00 pm	

04:00	Coffee Break
04:30 pm	

04:30	WS 3: Hematopoiesis, immune response and atherosclerosis	WS 4: Lipidomics
05:50 pm		

SATURDAY, DECEMBER 14, 2019

08:15	Poster Session & Coffee Break
10:00 am	

10:00 am	Plenary Session 3
12:00 pm	

12:00	Lunch Break
12:30 pm	

12:30	Symposium — Akcea Therapeutics Germany GmbH
01:30 pm	“Triglycerides: Fat in the blood – an underdiagnosed risk”

01:30	WS 5: Lipid metabolism, steroid hormones and vascular diseases	WS 6: Non coding RNA and atherosclerosis
02:50 pm		

FRIDAY | DECEMBER 13, 2019

FR

08:30 –
10:00 am

Plenary Session 1

Chairs: J. Thiery (Germany), C. Weber (Germany)



⌚ Room
4+5

Novel gene candidates for cardiovascular and lipid diseases

H. Schunkert (Germany)

Cross-talk between lipids and cells in the culprit atherosclerotic lesion

C. Weber (Germany)

Novel therapeutic approaches for metabolic diseases

T. Tschöp (Germany)

10:00 –
10:30 am

Coffee Break

10:30 am –
12:30 pm

WS 1: Lipids, fatty liver and obesity

Chairs: M. Blüher (Germany), R. Burkhardt (Germany)



⌚ Room
1

Obesity and inflammation

M. Blüher (Germany)

How macrophages can control adipocytes

M. Keuper (Germany)

Lipolysis in brown adipose tissue

J. Heeren (Germany)

Effect of dietary modifiers on CVD parameters- insights from long-term, large scale RCTs

G. Tsabani (Israel)

Role of Hepatokines in Nonalcoholic Fatty Liver Disease

N. Stefan (Germany)

Polyunsaturated fatty acids suppress the effect of inflammatory mediators on cellular miRNA expression

D. Maucher (Germany)

10:30 am –
12:30 pm

WS 2: Risk factors and preventive strategies in cardiometabolic and brain diseases

Chairs: M. Westerterp (Netherlands), F. Kronenberg (Austria)



⌚ Room
4+5

Crosstalk of cholesterol with the inflammasome

M. Westerterp (Netherlands)

NLRP3 inflammasome and atherosclerosis

P. Duewell (Germany)

Novel strategies in the prevention of coronary heart disease and heart failure

U. Laufs (Germany)

The metabolic axis of nutrition and the brain

I. Bechman & U. Ceglarek (Germany)

Challenges in PCSK-9 analysis

H. Tavori (United States)

Novels in the epidemiology of Lp(a) and other lipoproteins

F. Kronenberg (Austria)


12:30 – 01:15 pm	Lunch Break	
01:15 – 02:15 pm	Symposium — Daiichi Sankyo Deutschland GmbH “Beyond statins: upcoming options in cholesterol therapy”	
02:30 am – 04:00 pm	Plenary Session 2 <i>Chairs: E. Fisher (United States), U. Laufs (Germany)</i>	
⌚ Room 4+5	Macrophages in many guises in atherosclerosis and its regression <i>E. Fisher (United States)</i> Monocyte/Macrophage Interactions in Myocardial Infarction <i>I. Hilgendorf (Germany)</i> Clonal hematopoiesis a newly recognized, common and potent driver of cardiovascular disease <i>P. Libby (United States)</i>	
04:00 – 04:30 pm	Coffee Break	
04:30 – 05:50 pm	WS 3: Hematopoiesis, immune response and atherosclerosis <i>Chairs: T. Chavakis (Germany), U. Platzbecker (Germany)</i>	
⌚ Room 1	Dyslipidemia and the immune system <i>E. Lutgens (Netherlands)</i> Inflammation and atherosclerosis <i>H. Sager (Germany)</i> Myelopoiesis and trained immunity <i>T. Chavakis (Germany)</i> Crosstalks of lipids with monocyte / macrophages <i>G. Schmitz (Germany)</i>	
04:30 – 05:50 pm	WS 4: Lipidomics <i>Chairs: U. Cegłarek (Germany), P. Rosenstiel (Germany)</i>	
⌚ Room 4+5	Progress in New Generation Sequencing (DFG Competence Centre for Genome Analysis) <i>P. Rosenstiel (Germany)</i> LC-MS/MS analysis of lipid metabolism <i>M. Fedorova (Germany)</i> Challenges of lipid analytics with gas chromatography-mass spectrometry <i>D. Lütjohann (Germany)</i> Quantitative Lipidomics - methods, applications and standardization <i>G. Liebisch (Germany)</i>	

SATURDAY | DECEMBER 14, 2019

SA

08:15 – 10:00 am	Poster Session & Coffee Break <i>Chairs: G. Siegert (Germany), J. Heeren (Germany)</i>	
10:00 am – 12:00 pm	Plenary Session 3 <i>Chairs: D. Seidel (Germany), B. Isermann (Germany)</i>	
⌚ Room 4+5	<p>Risk factor hyperchylomicronemia? <i>B. Nordestgaard (Denmark)</i></p> <p>Structure-Function-Disease Relationships of HDL – implications for diagnostics and therapy <i>A. von Eckardstein (Switzerland)</i></p> <p>Update of lipid metabolism of the brain <i>J. Herz (United States)</i></p> <p>Coagulation in atherosclerosis - a role beyond blood clotting <i>B. Isermann (Germany)</i></p>	
12:00 – 12:30 pm	Lunch Break	
12:30 – 01:30 pm	Symposium — Akcea Therapeutics Germany GmbH “Triglycerides: Fat in the blood – an underdiagnosed risk”	
01:30 – 02:50 pm	WS 5: Lipid metabolism, steroid hormones and vascular diseases <i>Chairs: J. Kratzsch (Germany), M. Laudes (Germany)</i>	
⌚ Room 1	<p>Lipid metabolism and inflammatory response <i>M. Laudes (Germany)</i></p> <p>Genome wide analysis of steroid hormones and the genetic risk for CHD <i>J. Pott (Germany)</i></p> <p>Steroids and stress response <i>Y. Bae (Austria)</i></p> <p>Toward functional understanding of novel genes associated with plasma lipids and atherosclerosis <i>R. Burkhardt (Germany)</i></p>	
01:30 – 02:50 pm	WS 6: Non coding RNA and atherosclerosis <i>Chairs: Y. Devaux (Luxembourg), T. Kaiser (Germany)</i>	
⌚ Room 4+5	<p>Non-coding RNAs in the cardiovascular system <i>I. Devaux (Luxembourg)</i></p> <p>Non-coding RNAs in plaque (de)stabilization <i>L. Maegdefessel (Germany)</i></p> <p>Lipid-Associated Macrophage (LAM) Cells Control Metabolic Homeostasis <i>L. Adlung (Israel)</i></p> <p>Identifying the role of cardiolipins for cardiac function in Drosophila melanogaster <i>S. Leberer (Germany)</i></p>	

EXHIBITION



COMPANY	BOOTH
Akcea Therapeutics Germany GmbH	1
AlphaScience GmbH	2
Chromsystems GmbH	3
Olink Proteomics	4
Denka Seiken Co., Ltd.	5
Sarstedt AG & Co. KG	6
Sable Systems Europe GmbH	7
Daiichi-Sankyo Deutschland GmbH	8

SPONSORS



In accordance with the requirements for certification by the State Medical Association, we disclose the financial support of all supporters at the conference homepage under the following weblink:
<https://www.lipidmeeting.de/support>



*Test early.
Treat right.
Save lives.*

Paradigmenwechsel bei Herzinsuffizienz

Schaffen Sie Klarheit bei Herzinsuffizienz unter ARNI¹ Therapie

- Patienten mit Herzinsuffizienz profitieren von einer Behandlung mit der neuen ARNI Wirkstoffklasse²
- Nicht alle kardialen Biomarker eignen sich für die Verlaufskontrolle unter der neuen ARNI Therapie³
- NT-proBNP bleibt auch unter ARNI Therapie ein zuverlässiger Biomarker für Patienten mit Herzinsuffizienz⁴



Weiterführende Informationen finden
Sie unter **roche.de/ntprobpn**

¹ ARNI Angiotensin Rezeptor – Neprilysin Inhibitor

² Packer, J.J.V. et al. (2014), *Circulation*, 131, 54-61.

³ Mair, J. et al. (2016), Acute Card Care. *Eur Heart J.*

⁴ Entresto. Summary of Product Characteristics.

EMA approval.



Roche Diagnostics Deutschland GmbH
Sandhofer Straße 116
68305 Mannheim
www.roche.de
© 2017 Roche Diagnostics
Alle Rechte vorbehalten.

NEU

EINZIGE ZUGELASSENE MEDIKAMENTÖSE THERAPIE DES **FAMILIÄREN CHYLOMI- KRONÄMIE SYNDROMS** NEBEN EINER DIÄT¹

- Senkt die Triglyceride¹
 - Reduziert die Häufigkeit von Pankreatitis¹

¹ Waylivra Fachinformation. Stand August 2019.

Waylivra 285 mg Injektionslösung in einer Fertigspritze.

QUALITATIVE UND QUANTITATIVE ZUSAMMENSETZUNG: **Wirkstoff:** Volanesorsen. Jede Einzeldosis-Fertigspritze enth. 285 mg Volanesorsen in 1,5 ml Lösung. **Sonst. Bestandt.:** Natriumhydroxid (zur pH-Einstellung) Salzsäure (zur pH-Einstellung). Wasser f. Injektionszwecke. **Wirkstoffgruppe:** Mittel, die den Lipidstoffwechsel beeinflussen; andere Mittel, die den Lipidstoffwechsel beeinflussen ATC-Code: C10AX. **ANWENDUNGSGBIETE:** f. d. unterstützende Behandlung neben e. Diät b. erwachsenen Patienten mit genetisch bestätigter Familiär Chylomikronämie Syndrom (FCS) und e. hohen Risiko f. Pankreatitis, bei d. das Ansprechen auf e. Diät und e. triglyceridsensible Therapie unzureichend war. **GEGENANZEIGEN:** Überempf. gegen d. Wirkstoff o. einen d. sonst. Bestandt., chronische o. ursächlich unklare Thrombozytopenie; B. Thrombozytopenie (Thrombozyten < 140 x 10⁹/l) darf d. Therapie nicht eingeleitet werden. **NEBENWIRKUNGEN:** Sehr häufig: Thrombozytopenie; a. d. Injektionsstelle: Hautrotung; Schmerzen, Blässe, Schwellung, Juckreiz, Hautverfärbung, Verhärtung, blauer Fleck, Odem; Thrombozytenzahl vermind. Häufig: Leukopenie; Eosinophilie; immunthrombozytopenische Purpura; spontane Hamatombildung; Impfreakt.; Hypersensitivität; serumkrankheitsähnliche Reakt.; Diabetes mell.; Schlaflosigkeit; Kopfschm.; Hypästhesie; Präsynkope; retinale Migräne; Synkope; Schwindelgefühl; Tremor; konjunktivale Blutung; Verschwommensehen; Hamatombildung; Hyper-tonie; Blutung; Hitzewallungen; Epistaxis; Husten; Dyspnoe; verstopfte Nase; Pharynxödem; Giemen; Übelkeit; Diarrhoe; Munddrockenheit; Zahnfleischbluten; Mundschleimhautblutung; Speicheldrüsenvergrößerung; Erbrechen; Bauchschm.; Blähungen; Dyspepsie; Gingiveschwellung; Erythem; Pruritus; Urtikaria; verstarktes Schwitzen; Hautausschlag; Petechien; Ekchymosen; Nachtschweiß; Papel; Hypertrophie d. Haut; Gesichtsschwellung; Myalgien; Arthralgien; Gliederschm.; Arthritis; Rückenschm.; muskuloskelettale Schm.; Nackenschm.; Muskelkrämpfe; Gelenksteife; Myositis; Kieferschm.; Polymyalgia rheumatica; Hämaturie; Proteinurie; Asthenie; Abgeschlagenheit; a. d. Injektionsstelle: Hamatom; Reaktion; Urtikaria; trockene Haut; Blutung; Hypästhesie; Bläschenbildung; Missemppfindungen; Entzündung; Gewebevermehrung; Parästhesien; Schorf; Papel; Überwärmung d. Injektionsstelle; Schüttelfrost; Fieber; Unwohlsein; Hitzegefühl; grippeähnliches Krankheitsbild; Schmerzen; Odem; nichtkardiale Thoraxschmerzen; Blutung a. einer Gefäßpunktionstelle; renale Kreatinin-Clearance; Leukozytenzahl; Hämoglobin vermind.; Serumkreatinin; Serumharnstoff; Transaminasen; Leberenzymwert; INR erhöht; Kontusion. **STAND D. INFORMATION:** August 2019. **INHABER DER ZULASSUNG:** Akcea Therapeutics Ireland Ltd., Regus House, Harcourt Centre, Harcourt Road, Dublin 2, Irland. DE **VERSCHREIBUNGSPFLICHTIG, AT REZEPTE-, APOTHEKENPFLICHTIG.**

▼ Dieses Arzneimittel unterliegt einer zusätzlichen Überwachung. Diese ermöglicht eine schnelle Identifizierung neuer Erkenntnisse über die Sicherheit. Angehörige von Gesundheitsberufen sind aufgefordert, jeden Verdachtsfall einer Nebenwirkung zu melden. Deutschland: Nebenwirkungen sollen dem BfArM angezeigt werden. Formulare und weitere Informationen finden Sie unter www.bfarm.de. Österreich: Nebenwirkungen sollen dem Bundesamt für Sicherheit und Gesundheitswesen (BASG) angezeigt werden. Formulare und weitere Informationen erhalten Sie unter www.basg.gv.at.